Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Date:2/4/2009

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles-

TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the primary efficacy endpoint in the first stage of its ongoing Phase II clinical trial in patients with non-small cell lung cancer (NSCLC). The open-label, Simon two-stage study is designed to evaluate the safety and efficacy of the combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel in NSCLC patients. Seventeen of the 21 patients enrolled in Stage A were deemed evaluable for tumor response by the end of four treatment cycles, with six patients achieving partial tumor responses and one patient achieving a complete tumor response, according to RECIST criteria. These preliminary results exceed the pre-specified benchmark criteria established for enrolling an additional 28 patients in Stage B of this trial, up to a total of 49 patients.

"We are very pleased with the promising early results from this pilot Phase II lung cancer trial and will now move forward to initiate the second stage of the study," said Steven W. King, president and CEO of Peregrine. "We are encouraged by the number of tumor responses seen at this early time point of approximately 12 weeks in patients with NSCLC, a leading cause of cancer deaths that responds poorly to current treatments. As these patients continue on treatment, we will be assessing them for further signs of anti-tumor activity, and we look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial in patients with previously untreated locally advanced or metastatic NS
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
4. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
7. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
8. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
11. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Ardelyx, ... biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic ... quarter 2014 financial results on Thursday, November 6, ... will host a live conference call and webcast ... results and provide a business update. ...
(Date:10/30/2014)... 30, 2014 On October 26th ... Showcase in Chicago, leading applied stem cell research ... Wade McKenna presented talks on New Techniques for ... Applications For Stem Cells. , Dr. Riordan focused ... the properties of AlphaGEMS that include: wound healing; ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 2014 Avure Technologies celebrates a year of ... member of its fleet of high volume High Pressure Processing ... as we return to PackExpo this year, which is where ... Vegas,” said Jeff Williams, CEO at Avure. “Sales of the ... to be meeting the challenges of market demand for higher ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... EMERYVILLE, Calif., Sept. 17 Neurobiological Technologies, Inc. (Nasdaq: ... 15, 2009, it received a letter from The Nasdaq Stock ... has closed below $1.00 per share for 30 consecutive business ... $1.00 per share is a deficiency under Nasdaq,s requirements for ...
... , , EAST HANOVER, N.J., ... approved Valturna(R) (aliskiren and valsartan) tablets, the first and only medicine ... as the renin angiotensin aldosterone system (RAAS), an important regulator of ... indicated for the treatment of high blood pressure in patients not ...
... , ABBOTT PARK, Ill., Sept. 17 The board of directors ... of 40 cents per share. , , This marks ... The cash dividend is payable Nov. 15, 2009, to shareholders of record at ... Abbott has increased its dividend payout for 37 consecutive years - including an ...
Cached Biology Technology:Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7
(Date:10/29/2014)... suggesting air pollutants released by unconventional oil and gas ... is published today in the open access journal ... and formaldehyde were found. The study is the first ... live near production sites and could be used to ... gas come from reserves that do not readily flow ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
(Date:10/29/2014)... their food, but they also need protection from its harmful ... of molecules in plants that shields them from sun damage. ... American Chemical Society , one team reports on the mechanics ... and colleagues at Purdue University note that the harsh ultraviolet ... to plant DNA and, as a result, hinder plant growth. ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... -- New research is shedding light on the preferred habitat ... often overlooked species in Arctic marine food webs. Squid, ... important role as prey in Arctic waters for species such ... Kathleen Gardiner, a PhD candidate in the Biological Sciences Department ...
... -- Montana State University historian Timothy J. LeCain recently ... best new book in environmental history. The ... that Wired America and Scarred the Planet," tells the ... Berkeley Pit in Butte, Mont., and the Bingham ...
... 7, 2010) More than 1600 genetics researchers who use ... to study basic aspects of biology ranging from memory to ... underlie evolution, will be gathering in Washington, DC, for the ... Genetics Society of America, and beginning this evening at the ...
Cached Biology News:Habitat of elusive Northern squid documented by researcher 2Montana State University historian wins prize for book on Montana, Utah copper mines 2Drosophilists fly into DC for 51st Annual Drosophila Research Conference 2